Sequence,
Small RNA,
RNA editing,
Potency,
Durability,
Health,
...Continued,
RNA,
MD,
Doctor of Philosophy,
Weight loss,
IND,
CNS,
Obesity,
Oligonucleotide,
GSK,
Patient,
Medicinal chemistry,
MBA,
Liu Wei,
Clinical trial,
Pharmaceutical industry CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today provided an update on its best-in-class small interfering RNA (siRNA) and RNA editing platform capabilities.
Key Points:
- As part of Wave’s ongoing collaboration with GSK, GSK has selected its first two programs to advance to development candidates following achievement of target validation.
- GSK will provide an aggregate initiation payment of $12 million to Wave for these two oligonucleotide programs.
- Under the agreement, GSK can advance up to eight programs leveraging Wave’s PRISM™ platform and multiple RNA-targeting modalities (RNA editing, splicing, siRNA, and antisense) with target validation work ongoing across multiple therapy areas.
- Beyond these programs, our collaboration is focusing on all Wave modalities, including RNA editing.
Retrieved on:
Wednesday, March 27, 2024
CAMBRIDGE, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences in April.
Key Points:
- CAMBRIDGE, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences in April.
- Analyst-led fireside chat presentation time: 3:10 p.m.
- ET
Live webcasts of these presentations will be available on the Investor Relations page of the Wave Life Sciences website at http://ir.wavelifesciences.com .
- Replays of these presentations will be archived and available on the site for a limited time following the event.
Therapy,
Facial muscles,
Pharmacology,
Central nervous system,
Research,
GSK,
MD,
Liver disease,
Dystrophin,
Obesity,
Cerebrospinal fluid,
N-Acetylgalactosamine,
HD,
Weight loss,
DMD,
Duchenne muscular dystrophy,
Lof,
Exercise,
Lipolysis,
Exon,
MBA,
Conference,
Wave,
Activin and inhibin,
AATD,
Health,
Safety,
Biomarker,
RNA,
Greenshoe,
Genetics,
Pharmacokinetics,
Webcast,
Patient,
Clinical trial,
HTT,
Q&A,
Small RNA,
Serum,
Episcopal conference,
Human,
Coronary artery disease,
Pharmaceutical industry In the fourth quarter of 2023, Wave initiated dosing in RestorAATion-1, which resulted in a $20 million milestone payment from GSK.
Key Points:
- In the fourth quarter of 2023, Wave initiated dosing in RestorAATion-1, which resulted in a $20 million milestone payment from GSK.
- Revenue was $29.1 million for the fourth quarter of 2023 as compared to $1.2 million in the prior year quarter.
- Net loss was $16.3 million for the fourth quarter of 2023 as compared to $43.7 million in the prior year quarter.
- ET to review the fourth quarter and full year 2023 financial results and pipeline updates.
Retrieved on:
Wednesday, February 28, 2024
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m.
Key Points:
- CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m.
- ET on Wednesday, March 6, 2024, to review the company’s fourth quarter and full year 2023 financial results and provide business updates.
- The webcast and conference call may be accessed by visiting “Investor Events” on the investors section of the Wave Life Sciences website: ir.wavelifesciences.com/events-publications/events .
- Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website.
Retrieved on:
Tuesday, February 27, 2024
B cell,
Therapy,
Pharmacology,
Diaphragm,
Chemistry,
Dystrophin,
DMD,
Part,
Facial muscles,
Duchenne muscular dystrophy,
Exon,
Conference,
Wave,
Health,
Muscular Dystrophy Association,
RNA,
PN,
Optimism,
Protein,
Oligonucleotide,
RAPS,
Half-life,
MDA,
Episcopal conference,
Dietary supplement CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced its upcoming presentations at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place March 3-6 in Orlando, FL.
Key Points:
- Wave’s poster presentations will highlight the best-in-class potential of WVE-N531 in Duchenne muscular dystrophy (DMD), which is currently being evaluated in the Phase 2, potentially registrational FORWARD-53 study.
- The presentations will also illustrate the impact of Wave’s novel PN chemistry on pharmacology of its exon skipping oligonucleotides.
- These data suggest that WVE-N531 muscle concentrations in the clinic may be higher in heart and diaphragm than in skeletal muscle.
- “At Wave, we increasingly continue to regard exon skipping as the preferred mechanism for altering DMD disease progression in those amenable to this approach.
Well,
RNA,
Conference,
Science,
Wave,
Messenger,
Research,
AAT,
Chemistry,
Pizzicato,
Small RNA,
Lung,
Weight,
Health,
Disease,
MBA,
MD,
Mouse,
HD,
Human,
Serum,
GSK,
Mutation,
Genetics,
Coronary artery disease,
Obesity,
Genomics,
Concentration ratio,
Central nervous system,
Patient,
Liver disease,
Lof,
HTT,
Medicine,
Therapy,
Oligonucleotide,
NHP,
CTA,
Vaccine We expect 2024 will be an inflection year that will drive significant value for Wave, our shareholders, and most importantly, for the patients who will benefit from our research,” said Paul Bolno, MD, MBA, President and Chief Executive Officer of Wave Life Sciences.
Key Points:
- We expect 2024 will be an inflection year that will drive significant value for Wave, our shareholders, and most importantly, for the patients who will benefit from our research,” said Paul Bolno, MD, MBA, President and Chief Executive Officer of Wave Life Sciences.
- Expected milestones: Wave plans to deliver proof-of-mechanism data in individuals with AATD in 2024.
- Expected milestones: Wave expects to deliver data, including dystrophin protein expression from muscle biopsies at 24 weeks, in the third quarter of 2024.
- A live webcast of this presentation will be available on the Investor Relations page of the Wave Life Sciences website at http://ir.wavelifesciences.com .
Retrieved on:
Wednesday, January 3, 2024
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2024, at 3:00 p.m. PT / 6:00 p.m.
Key Points:
- CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2024, at 3:00 p.m. PT / 6:00 p.m.
- ET.
- A live webcast of this presentation will be available on the Investor Relations page of the Wave Life Sciences website at http://ir.wavelifesciences.com .
- Replay of this presentation will be archived and available on the site for a limited time following the event.
Retrieved on:
Friday, December 15, 2023
RNA,
Wave,
Diaphragm,
Duchenne muscular dystrophy,
Disease,
Clinical trial,
Heart,
Pharmacokinetics,
RAPS,
Part,
DMD,
Safety,
Dystrophin,
Therapy,
Medical imaging CAMBRIDGE, Mass., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced the initiation of dosing in the Phase 2 FORWARD-53 clinical trial, which is evaluating WVE-N531 as a treatment for boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping. FORWARD-53 is designed to assess functional dystrophin protein at 24 and 48 weeks with every other week dosing of WVE-N531.
Key Points:
- FORWARD-53 is designed to assess functional dystrophin protein at 24 and 48 weeks with every other week dosing of WVE-N531.
- Importantly, in our non-human primate studies, muscle concentrations were higher in the diaphragm and heart than in skeletal muscle.
- Additionally, while FORWARD-53 is dosing every other week, we have the potential for monthly dosing in the future.
- The trial is powered to evaluate functional, endogenous dystrophin expression following 24 and 48 weeks of every other week, intravenous dosing at 10 mg/kg.
Retrieved on:
Thursday, December 7, 2023
Telephone,
RNA,
J.P. Morgan & Co.,
Sale,
Mizuho,
State Street,
SVB Securities,
J. P. Morgan,
Prospectus,
Broadridge Financial Solutions,
Truist,
Security (finance) CAMBRIDGE, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today the pricing of its previously announced underwritten public offering of 20,000,000 of its ordinary shares at a price to the public of $5.00 per ordinary share.
Key Points:
- CAMBRIDGE, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today the pricing of its previously announced underwritten public offering of 20,000,000 of its ordinary shares at a price to the public of $5.00 per ordinary share.
- Gross proceeds to Wave Life Sciences from the offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and offering expenses.
- All of the ordinary shares in the offering are being sold by Wave Life Sciences.
- In addition, Wave Life Sciences has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 of its ordinary shares on the same terms and conditions.
Retrieved on:
Wednesday, December 6, 2023
Telephone,
RNA,
J.P. Morgan & Co.,
Wave,
Sale,
State Street,
SVB Securities,
J. P. Morgan,
Prospectus,
Broadridge Financial Solutions,
Security (finance) CAMBRIDGE, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that it has commenced an underwritten public offering of $100 million in aggregate of its ordinary shares, and, to certain investors that so choose in lieu of ordinary shares, pre-funded warrants to purchase ordinary shares.
Key Points:
- CAMBRIDGE, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that it has commenced an underwritten public offering of $100 million in aggregate of its ordinary shares, and, to certain investors that so choose in lieu of ordinary shares, pre-funded warrants to purchase ordinary shares.
- In connection with the offering, Wave intends to grant the underwriters a 30-day option to purchase ordinary shares in an amount up to an additional 15% of the total amount of ordinary shares and pre-funded warrants sold in the public offering on the same terms and conditions.
- All of the securities in the offering will be sold by Wave Life Sciences.
- The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.
